Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Enrollment opens in phase IIb study of ARO-APOC3 in severe hypertriglyceridemia

May 31, 2021

Studies reveal efficacy of OTL-101 gene therapy in treating ADA-SCID

May 27, 2021

Promising liver-specific AAV gene therapy for glycogen storage disease type 1A

May 27, 2021

Spruce Biosciences reports phase IIa data on tildacerfont in classic congenital adrenal hyperplasia

May 26, 2021

Sparrow Pharmaceuticals presents new data on SPI-62 for Cushing's syndrome

May 26, 2021

Phase I data presented for MEDI-6570 in patients with T2DM

May 26, 2021

GR antagonist CORT-125329 shows selectivity and activity in vitro and in vivo

May 26, 2021

BBP-711 enters phase I healthy volunteer study

May 21, 2021

Phase Ib data for cagrilintide plus semaglutide in overweight or obese subjects

May 21, 2021

JD Bioscience presents 5-HT2A receptor antagonists

May 21, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.